Biological and Clinical Sciences Research Journal eISSN: 2708-2261; pISSN: 2958-4728 www.bcsrj.com DOI: https://doi.org/10.54112/bcsrj.v2023i1.271 Biol. Clin. Sci. Res. J., Volume, 2023: 271 [Citation Kamran, M., Mukhtar, M., Ali, M., Umair, M., Ahmed, A. (2023). Comparing the effects of loading dose of rosuvastatin vs atorvastatin on immediate post-perfusion TIMI flow in primary PCI patient. Biol. Clin. Sci. Res. J., 2023: 271. doi: https://doi.org/10.54112/bcsrj.v2023i1.271] 1 Original Research Article COMPARING THE EFFECTS OF LOADING DOSE OF ROSUVASTATIN VS ATORVASTATIN ON IMMEDIATE POST-PERFUSION TIMI FLOW IN PRIMARY PCI PATIENT KAMRAN M *1 , MUKHTAR M 2 , ALI M 1 , UMAIR M 3 , AHMED A 1 1 Department of Medicine, Mayo Hospital, Lahore, Pakistan 2 Department of Pediatrics Medical Unit 1, Mayo Hospital Lahore, Pakistan 3 Department of Internal Medicine, Mayo Hospital, Lahore, Pakistan *Correspondence author email address: khawajakamran220@gmail.com (Received, 19 th November 2022, Revised 15 th March 2023, Published 10 th May 2023) Abstract: The use of statins in patients undergoing primary percutaneous coronary intervention (PCI) is associated with improved outcomes, but the optimal statin type and loading dose remain unclear. This randomized controlled trial aimed to compare the effects of a loading dose of rosuvastatin versus atorvastatin on immediate post-PCI Thrombolysis In Myocardial Infarction (TIMI) flow and left ventricular ejection fraction (LVEF) at hospital discharge in patients with ST-elevation myocardial infarction (STEMI). 300 patients were enrolled at Mayo Hospital, Lahore, from June 2022 to December 2022. Patients were randomized to receive either a loading dose of rosuvastatin (40 mg) or atorvastatin (80 mg) before primary PCI. There was no significant difference in the proportion of patients achieving TIMI flow grade 3 immediately after PCI between the rosuvastatin and atorvastatin groups (74% vs. 72%, p=0.67). However, the rosuvastatin group had a higher mean LVEF at hospital discharge than the atorvastatin group (55.6% vs. 52.2%, p=0.02) after adjusting for various confounding factors using multivariable linear regression analysis. The two groups had no significant difference in peak CK-MB levels or adverse events. Based on the results, it can be concluded that in patients undergoing primary PCI, there was no significant difference in the proportion of patients achieving TIMI flow grade 3 immediately after PCI between a loading dose of rosuvastatin and atorvastatin. Keywords: Statins, , Rosuvastatin, Atorvastatin, Randomized Controlled Trial, ST-Elevation Myocardial Infarction, Peak CK-MB Levels, Multivariable Linear Regression Analysis. Introduction Cardiovascular disease is a leading cause of morbidity and mortality worldwide, with acute myocardial infarction (AMI) being a common manifestation. PCI is the norm for patients with ST-fragment height localized myocardial necrosis (STEMI). The objective of essential PCI is to reestablish the typical bloodstream to the blocked coronary course and the breaking point of the degree of myocardial harm (Tobert, 2003). Statins, otherwise called HMG-CoA reductase inhibitors, have been displayed to have beneficial impacts in lessening cardiovascular bleakness and mortality. Studies have demonstrated how statins can improve the clinical results in patients with AMI by decreasing aggravation, balancing out atherosclerotic plaques, and working on endothelial capability (Luvai et al., 2012). The stacking portion of statin treatment has likewise been displayed to further develop the prompt post-perfusion TIMI stream and clinical results in patients with AMI. Rosuvastatin and atorvastatin are two generally involved statins in the administration of AMI. Be that as it may, there is restricted information contrasting the impacts of stacking a portion of rosuvastatin versus atorvastatin on quick post-perfusion TIMI stream in patients undergoing essential PCI (Nissen et al., 2005). The quick post-perfusion TIMI stream is a pivotal indicator of clinical results in patients with STEMI undergoing essential PCI. The level of the TIMI stream can give an understanding of the degree of myocardial harm and the probability of unfriendly cardiovascular occasions. Hence, further developing prompt post-perfusion TIMI stream is a significant and helpful objective in the administration of STEMI (Cannon et al., 2004). Studies have demonstrated how stacking a portion of statins can further develop the prompt post-perfusion TIMI stream in patients with STEMI undergoing essential PCI. In any case, the similar adequacy of various statins in such a manner isn't deep-rooted (O'gara et al., 2013). Rosuvastatin and atorvastatin have been displayed to have comparative impacts in lowering lipid levels, yet they vary in their pharmacokinetic properties and